Saturday, Jan 31st

Last update02:11:08 PM GMT






You are here: News BioMedTech

Dazzling Disley a City slicker after winning Quoted Company Award

Paul Morrill with Darrin-DisleyHorizon Discovery CEO Darrin Disley has scooped another major accolade after being named Entrepreneur of the Year at last night’s Quoted Company Awards 2014 in London.

AstraZeneca and Sanger leverage gene technology for drug discovery

Mene-Pangalos AstraZenecaAstraZeneca, which is building its bulk in the Cambridge UK life science cluster, is harnessing the power of bleeding edge gene editing technology to boost future drug development.

Pharma giant Merck buys Cambridge software

Merck-KGaA-Thomas-QuesteData management software from CRedit360 in Cambridge UK has been bought by global chemical and pharmaceutical heavyweight Merck to help improve the consistency of its global sustainability data management and reporting.

Endomag’s cancer diagnostic trial underway in US

Endomag- eric mayesPivotal trials using Cambridge UK medical technology to fight breast cancer are underway at six sites across the United States.

Cambridge mourns death of life science entrepreneur Geraldine Rodgers

Dr-Geraldine-RodgersDr Geraldine Rodgers, a founding director, seed investor and non-executive director in Cambridge gene editing company Horizon Discovery and former head of seed funds for the university’s commerialisation arm, Cambridge Enterprise, has died after a long battle with lung cancer. She was 66.

Sphere Medical builds sales pipeline for new diagnostic device

Sphere-Medical Wolfgang RenckenDiagnostic technology specialist Sphere Medical has revealed a surge in sales prospects for its new device Proxima 3 from potential customers in the UK and Europe as it builds commercial capability.

M11 corridor fast-tracks life science glory for UK

Harriet Fear, chief executive of One NucleusIn describing the current activities and dynamics of this part of the UK one needs to consider not just the immensely exciting growth of the Cambridge Cluster but also how the M11 is shaping up to be a cash flow highway for our high growth life science companies.

Cambridge biotech boost for US presidential hopeful

New Jersey Governor Chris Christie Cambridge is to host a biotech summit for life science executives to meet New Jersey Governor Chris Christie on his visit to the UK in early February.

Abcam paying $28m for US biomarker pioneer as growth in China soars

Alan-HirzelAbcam, the Cambridge UK life science tools supplier, has agreed to pay $28 million cash for a US company commercialising technology developed at MIT.

Cambridge leads VC investment boom in UK biotech

Eliot-ForsterThe Cambridge medical technology cluster is leading an upsurge of VC investment into UK biotech.

Cambridge biotech sitting on near $500m gold mine

Horizon-Disley-2014The relentless rise of Cambridge personalised medicines pioneer Horizon Discovery was re-emphasised  today when the company revealed it was sitting on an R & D milestones and product royalties gold mine in a trading update to the UK market.

Bristol-Myers Squibb starts cancer trial with F-star technology

John-HaurumBristol-Myers Squibb has initiated a Phase 1 trial in the US of Cambridge UK company F-star’s lead compound – FS102 – to treat HER2-positive breast and gastric cancer.

Disease diagnostic tech secures $2.4m funding

Fluidic-Analytics-Cambridge-UniversityFluidic Analytics Limited, a technology spinout from the UK‘s University of Cambridge, has raised £1.56 million ($2.4 million) in a Series A financing led by Cambridge Enterprise and including DFJ Esprit, IQ Capital, Parkwalk Advisors and Amadeus Capital Partners as co-investors.

UroSens wins $3m and targets US with bladder and prostate cancer test

Ian-Campbell UroSensUroSens, a Cambridge UK company developing novel, non-invasive urine tests for the detection of prostate and bladder cancer, has received £2 million ($3.02 million) investment to commercialise the diagnostic technology.

Kymab works with global cancer leader on new drugs

Christian-GroendahlNew drugs to fight cancer, but with greater efficacy and less side effects, are to be developed by a global expert in the disease working with a Cambridge UK antibody technology company.

Cambridge firm helps French-US push for new HIV vaccines

Antitope collaborating with major organisations in France and the US Abzena subsidiary Antitope – based in the Cambridge UK medical technology heartland – is collaborating with major organisations in France and the US in a programme key to the development of two novel HIV vaccines.

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »

Page 1 of 69